Mesothelioma Drug Combination Continues to Show PromiseResearch & Clinical Trials
Asbestos.com is the nation’s most trusted mesothelioma resource
The Mesothelioma Center at Asbestos.com has provided patients and their loved ones the most updated and reliable information on mesothelioma and asbestos exposure since 2006.
Our team of Patient Advocates includes a medical doctor, a registered nurse, health services administrators, veterans, VA-accredited Claims Agents, an oncology patient navigator and hospice care expert. Their combined expertise means we help any mesothelioma patient or loved one through every step of their cancer journey.
More than 30 contributors, including mesothelioma doctors, survivors, health care professionals and other experts, have peer-reviewed our website and written unique research-driven articles to ensure you get the highest-quality medical and health information.
About The Mesothelioma Center at Asbestos.com
- Assisting mesothelioma patients and their loved ones since 2006.
- Helps more than 50% of mesothelioma patients diagnosed annually in the U.S.
- A+ rating from the Better Business Bureau.
- 5-star reviewed mesothelioma and support organization.
"My family has only the highest compliment for the assistance and support that we received from The Mesothelioma Center. This is a staff of compassionate and knowledgeable individuals who respect what your family is experiencing and who go the extra mile to make an unfortunate diagnosis less stressful. Information and assistance were provided by The Mesothelioma Center at no cost to our family."LashawnMesothelioma patient’s daughter
How to Cite Asbestos.com’s Article
Povtak, T. (2022, December 16). Mesothelioma Drug Combination Continues to Show Promise. Asbestos.com. Retrieved February 6, 2023, from https://www.asbestos.com/news/2020/05/04/mesothelioma-opdivo-yervoy-study/
Povtak, Tim. "Mesothelioma Drug Combination Continues to Show Promise." Asbestos.com, 16 Dec 2022, https://www.asbestos.com/news/2020/05/04/mesothelioma-opdivo-yervoy-study/.
Povtak, Tim. "Mesothelioma Drug Combination Continues to Show Promise." Asbestos.com. Last modified December 16, 2022. https://www.asbestos.com/news/2020/05/04/mesothelioma-opdivo-yervoy-study/.
Pharmaceutical giant Bristol Myers Squibb continues to tout its immunotherapy combination of Opdivo and Yervoy for first-line treatment of patients with pleural mesothelioma cancer.
Bristol Myers Squibb recently announced that overall survival “significantly improved” when the combination was measured against standard chemotherapy in a randomized, phase III clinical trial of previously untreated mesothelioma patients.
Its announcement was based on a pre-specific interim analysis conducted by the Data Monitoring Committee, a clinical study organization independent of Bristol Myers Squibb.
The study is being conducted at 114 centers throughout the world, including 14 across the United States.
“These topline results from the trial demonstrate the potential of Opdivo plus Yervoy in previously untreated patients with malignant pleural mesothelioma,” Dr. Sabine Maier, development lead of thoracic cancers at Bristol Myers Squibb, said in a press release.
Maier declined requests to provide additional insight to The Mesothelioma Center at Asbestos.com.
Opdivo/Yervoy Clinical Trial Continues for a Year
The chemotherapy regimen involved Alimta (pemetrexed) and either cisplatin or carboplatin. Opdivo (nivolumab) was administered every two weeks and Yervoy (ipilimumab) every six weeks, up to four times. Therapy was received until there was unacceptable toxicity, disease progression or for a maximum of two years.
This clinical trial is expected to continue until April 2021. It was designed to measure overall survival, objective response rate, disease control rate and progression-free survival.
None of the measurements were included in the news release provided by Bristol Myers Squibb, which indicated results would be saved for presentation at a future medical conference.
The Lancet Respiratory Medicine published a phase II study from the Netherlands in 2019 with the same immunotherapy combination used in second-line treatment. It reported a six-month disease control rate of 50% and a median progression-free survival of 6.2 months.
Another second-line, phase II study from France published by The Lancet Oncology in 2019 showed a median overall survival of 15.9 months and an average progression-free survival of 5.6 months with the immunotherapy combination.
Immunotherapy Drug Combination Can Increase Effectiveness
Pleural mesothelioma is a rare and aggressive cancer most often caused by an exposure to asbestos fibers. Median overall survival, based on numerous studies, is less than one year. The five-year survival rate is an estimated 10 percent.
Diagnosis of pleural mesothelioma often comes late. Less than one-third of those diagnosed qualify for potentially life-extending surgery.
Both Opdivo and Yervoy are aimed at better harnessing the body’s own immune system and promoting an anti-tumor response, but they work by targeting different surface proteins.
Negating those proteins allows the immune system to better recognize and attack tumor cells. Both drugs have shown effectiveness individually with many cancers, including mesothelioma. A synergy between the two can increase that effectiveness.
This combination also is being studied at three of the leading specialty centers in the United States as a precursor to aggressive surgery for mesothelioma. The Sidney Kimmel Cancer Center at Johns Hopkins University, MD Anderson Cancer Center at the University of Texas and the Greenebaum Cancer Center at the University of Maryland are hoping to enroll a combined 30 patients in the study.
The Opdivo/Yervoy combination received approval from the U.S. Food and Drug Administration for the treatment of metastatic melanoma in 2015.
Individually, Opdivo and Yervoy have become a treatment option for several cancers. In various studies they are being used together for advanced renal cell carcinoma, metastatic colorectal cancer and hepatocellular carcinoma.